HirudonucleodisulfideA is primarily investigated for its anticoagulant properties, making it relevant in the development of therapies targeting blood clot formation. It functions by interfering with key enzymes involved in the coagulation cascade, particularly those related to thrombin activity. This makes it a candidate for use in preventing thrombosis during surgical procedures or in patients with cardiovascular diseases.

Due to its unique disulfide-rich structure, it exhibits high stability and specificity, which enhances its potential as a lead compound in designing peptide-based anticoagulants. It has been studied in experimental models for intravenous anticoagulation, especially in settings where heparin use is contraindicated.

Additionally, HirudonucleodisulfideA shows promise in biomedical research as a tool for studying platelet aggregation and fibrin formation. Its application extends to surface coating of medical devices such as stents or catheters, where localized anticoagulation is beneficial to prevent device-related clotting.

Ongoing research explores its modified analogs for improved pharmacokinetics and reduced immunogenicity, aiming to develop safer and more effective antithrombotic agents.